dder tile long-term version Copaxone win European market, significant

Writer:ChingSource:Bio Valley Date:2017-07-14
  Industry analysts were surprised to learn that the Israeli pharmaceutical giant, Teva, had been able to successfully turn patients from Copaxone (1 injections a day) to a long-acting version of Copaxone (three times a week) at an alarming rate.
  Recently, the company is ready to 2015 early Copaxone to the European market. Copaxone (1 injections per day) is the world's best-selling multiple-sclerosis (MS) drug, which has a global sales volume of $4.33 billion in 2013, topping the list of the 2013 Global Multiple Sclerosis (MS) drug sales TOP10. However, Copaxone (1 injections per day) patents expire in the summer of 2015, when the drug will be hit by cheap generics. As a result, a long-term version of Copaxone's listing in major global markets is critical to the ladder and will be an important bargaining chip in defending its multiple sclerosis (MS) franchise.
  This Thursday, the Copaxone (3 injections per week) has reaped positive results in the European Union's decentralized review process (decentralised approvals procedure), which has issued a positive assessment of the long-acting version of MHRA by the EU reference member, the British Medicines and Health Products Authority (Copaxone) and other EU Member States (CMS). Long-term Copaxone is expected to be approved by all EU Member States within the next 1 months. Ladder has been planned in the first quarter of 2015 first in Germany, the Netherlands, Denmark launched a long-term version of Copaxone.
  In the United States, the long-acting version of Copaxone (40MG/ML, injected 3 times a week) was approved by the FDA in January 2014, and since the IPO, the number of prescription patients has reached 40,000. With the same indications as Copaxone (1 injections per day), long-acting version Copaxone is also used for the treatment of adult patients with recurrent multiple sclerosis (RMS).
  In the next 10 years, the Global multiple Sclerosis Market (MS) will grow at a 4% annual compound growth rate (CAGR) and $20 billion in 2023, according to a report released by decision Resources, the world's leading pharmaceutical and healthcare consultancy.
 

TypeInfo: Industry news

Keywords for the information:European markets 

error